vs
爱利金融（EFSI）与Protalix BioTherapeutics, Inc.（PLX）财务数据对比。点击上方公司名可切换其他公司
爱利金融的季度营收约是Protalix BioTherapeutics, Inc.的1.8倍（$16.4M vs $9.1M），爱利金融同比增速更快（21.3% vs -49.9%），爱利金融自由现金流更多（$24.3M vs $1.6M），过去两年爱利金融的营收复合增速更高（1.5% vs -6.7%）
爱利金融公司是一家注册于特拉华州的美国银行控股公司，总部位于密歇根州底特律市的爱利底特律中心。该公司提供多种金融服务，涵盖汽车金融、直营银行线上银行服务、企业贷款、车辆保险、按揭贷款，以及分期销售、租赁协议等相关融资服务。
Protalix BioTherapeutics是一家以色列制药企业，核心产品为植物源酶制剂他利苷酶阿尔法，该产品已获美国食品药品监督管理局批准，用于治疗戈谢病，专注于开发创新生物技术药物服务患者需求。
EFSI vs PLX — 直观对比
营收规模更大
EFSI
是对方的1.8倍
$9.1M
营收增速更快
EFSI
高出71.3%
-49.9%
自由现金流更多
EFSI
多$22.7M
$1.6M
两年增速更快
EFSI
近两年复合增速
-6.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $16.4M | $9.1M |
| 净利润 | — | $-5.5M |
| 毛利率 | — | 49.4% |
| 营业利润率 | 33.6% | -51.1% |
| 净利率 | — | -60.3% |
| 营收同比 | 21.3% | -49.9% |
| 净利润同比 | — | -184.8% |
| 每股收益（稀释后） | $1.10 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EFSIPLX
| Q4 25 | $16.4M | $9.1M | ||
| Q3 25 | $22.4M | $17.9M | ||
| Q2 25 | $20.6M | $15.7M | ||
| Q1 25 | $4.8M | $10.1M | ||
| Q4 24 | $22.0M | $18.2M | ||
| Q3 24 | $18.4M | $18.0M | ||
| Q2 24 | $16.5M | $13.5M | ||
| Q1 24 | $15.9M | — |
净利润EFSIPLX
| Q4 25 | — | $-5.5M | ||
| Q3 25 | $5.6M | $2.4M | ||
| Q2 25 | $5.3M | $164.0K | ||
| Q1 25 | $-7.0M | $-3.6M | ||
| Q4 24 | — | $6.5M | ||
| Q3 24 | $3.4M | $3.2M | ||
| Q2 24 | $3.2M | $-2.2M | ||
| Q1 24 | $2.5M | — |
毛利率EFSIPLX
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
营业利润率EFSIPLX
| Q4 25 | 33.6% | -51.1% | ||
| Q3 25 | 30.9% | 11.9% | ||
| Q2 25 | 31.8% | 7.5% | ||
| Q1 25 | -189.0% | -41.0% | ||
| Q4 24 | 36.8% | 39.6% | ||
| Q3 24 | 21.6% | 22.2% | ||
| Q2 24 | 22.9% | -18.0% | ||
| Q1 24 | 19.1% | — |
净利率EFSIPLX
| Q4 25 | — | -60.3% | ||
| Q3 25 | 25.0% | 13.2% | ||
| Q2 25 | 25.6% | 1.0% | ||
| Q1 25 | -145.8% | -35.8% | ||
| Q4 24 | — | 35.6% | ||
| Q3 24 | 18.6% | 18.0% | ||
| Q2 24 | 19.3% | -16.4% | ||
| Q1 24 | 16.0% | — |
每股收益（稀释后）EFSIPLX
| Q4 25 | $1.10 | $-0.06 | ||
| Q3 25 | $1.04 | $0.03 | ||
| Q2 25 | $0.98 | $0.00 | ||
| Q1 25 | $-1.53 | $-0.05 | ||
| Q4 24 | $1.74 | $0.10 | ||
| Q3 24 | $0.97 | $0.03 | ||
| Q2 24 | $0.89 | $-0.03 | ||
| Q1 24 | $0.72 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $14.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $188.8M | $48.2M |
| 总资产 | $1.9B | $82.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EFSIPLX
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
股东权益EFSIPLX
| Q4 25 | $188.8M | $48.2M | ||
| Q3 25 | $185.6M | $52.9M | ||
| Q2 25 | $179.6M | $49.9M | ||
| Q1 25 | $176.5M | $45.2M | ||
| Q4 24 | $119.0M | $43.2M | ||
| Q3 24 | $117.8M | $32.4M | ||
| Q2 24 | $111.1M | $28.6M | ||
| Q1 24 | $107.7M | — |
总资产EFSIPLX
| Q4 25 | $1.9B | $82.3M | ||
| Q3 25 | $1.9B | $82.3M | ||
| Q2 25 | $2.0B | $78.5M | ||
| Q1 25 | $1.9B | $73.9M | ||
| Q4 24 | $1.9B | $73.4M | ||
| Q3 24 | $1.9B | $61.6M | ||
| Q2 24 | $1.8B | $91.5M | ||
| Q1 24 | $1.8B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.8M | $2.0M |
| 自由现金流经营现金流 - 资本支出 | $24.3M | $1.6M |
| 自由现金流率自由现金流/营收 | 148.6% | 17.8% |
| 资本支出强度资本支出/营收 | 8.6% | 4.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $39.7M | $-13.6M |
8季度趋势，按日历期对齐
经营现金流EFSIPLX
| Q4 25 | $25.8M | $2.0M | ||
| Q3 25 | $8.2M | $-3.7M | ||
| Q2 25 | $2.6M | $-5.2M | ||
| Q1 25 | $5.8M | $-5.1M | ||
| Q4 24 | $18.8M | $4.0M | ||
| Q3 24 | $7.5M | $4.1M | ||
| Q2 24 | $-1.8M | $-3.6M | ||
| Q1 24 | $6.8M | — |
自由现金流EFSIPLX
| Q4 25 | $24.3M | $1.6M | ||
| Q3 25 | $7.8M | $-4.2M | ||
| Q2 25 | $2.3M | $-5.7M | ||
| Q1 25 | $5.3M | $-5.4M | ||
| Q4 24 | $17.7M | $3.6M | ||
| Q3 24 | $7.3M | $4.0M | ||
| Q2 24 | $-2.2M | $-3.8M | ||
| Q1 24 | $6.7M | — |
自由现金流率EFSIPLX
| Q4 25 | 148.6% | 17.8% | ||
| Q3 25 | 35.0% | -23.7% | ||
| Q2 25 | 11.2% | -36.2% | ||
| Q1 25 | 110.1% | -53.0% | ||
| Q4 24 | 80.6% | 19.6% | ||
| Q3 24 | 39.6% | 22.4% | ||
| Q2 24 | -13.6% | -28.1% | ||
| Q1 24 | 41.9% | — |
资本支出强度EFSIPLX
| Q4 25 | 8.6% | 4.4% | ||
| Q3 25 | 1.7% | 2.8% | ||
| Q2 25 | 1.3% | 2.8% | ||
| Q1 25 | 11.2% | 3.0% | ||
| Q4 24 | 4.6% | 2.3% | ||
| Q3 24 | 1.3% | 0.5% | ||
| Q2 24 | 2.6% | 1.3% | ||
| Q1 24 | 0.6% | — |
现金转化率EFSIPLX
| Q4 25 | — | — | ||
| Q3 25 | 1.47× | -1.58× | ||
| Q2 25 | 0.49× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | 2.19× | 1.27× | ||
| Q2 24 | -0.57× | — | ||
| Q1 24 | 2.65× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EFSI
| Asset Management | $6.0M | 37% |
| Other | $3.8M | 23% |
| Interchange Fees | $3.5M | 22% |
| Overdrawn Account Fees | $1.6M | 10% |
| Brokerage Commissions | $1.4M | 9% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
